Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 4, 2006, Pages 811-824

  Passweg, Jakob R ^a   Koehl, Ulrike ^b   Uharek, Lutz ^c   Meyer Monard, Sandrine ^d   Tichelli, André ^d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

adoptive immunotherapy; HLA mismatched stem cell transplants; NK alloreactivity; NK cells; NK DLI

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; BIOENGINEERING; CANCER IMMUNOTHERAPY; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; DONOR; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; T LYMPHOCYTE;

GRAFT REJECTION; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LEUKEMIA; TRANSPLANTATION, HOMOLOGOUS;

EID: 33748896674     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.06.004     Document Type: Review

References (65)

1. Robertson M.J., and Ritz J. Biology and clinical relevance of human natural killer cells. Blood 76 12 (1990) 2421-2438
2. Smyth M.J., Hayakawa Y., Takeda K., et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Reviews Cancer 2 11 (2002) 850-861
3. French A.R., and Yokoyama W.M. Natural killer cells and viral infections. Current Opinion in Immunology 15 1 (2003) 45-51
4. Moretta A., Bottino C., Mingari M.C., et al. What is a natural killer cell?. Nature Immunology 3 1 (2002) 6-8
5. Moretta L., and Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. The EMBO Journal 23 2 (2004) 255-259
6. Vilches C., and Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annual Review of Immunology 20 (2002) 217-251
7. Farag S.S., Fehniger T.A., Ruggeri L., et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100 6 (2002) 1935-1947
8. Borrego F., Kabat J., Kim D.K., et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Molecular Immunology 38 9 (2002) 637-660
9. Moretta A., Bottino C., Vitale M., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annual Review of Immunology 19 (2001) 197-223
10. Parham P., and McQueen K.L. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nature Reviews Immunology 3 2 (2003) 108-122
11. Lanier L.L. NK cell recognition. Annual Review of Immunology 23 (2005) 225-274
12. Barao I., and Murphy W.J. The immunobiology of natural killer cells and bone marrow allograft rejection. Biology of Blood and Marrow Transplantation 9 12 (2003) 727-741
13. Cooper M.A., Fehniger T.A., Turner S.C., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97 10 (2001) 3146-3151
14. Robertson M.J., Soiffer R.J., Wolf S.F., et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. The Journal of Experimental Medicine 175 3 (1992) 779-788
15. Henslee-Downey P.J. Allogeneic transplantation across major HLA barriers. Best Practice and Research Clinical Haematology 14 4 (2001) 741-754
16. Singhal S., Henslee-Downey P.J., Powles R., et al. Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission. Bone Marrow Transplantation 31 10 (2003) 889-895
17. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. The New England Journal of Medicine 339 17 (1998) 1186-1193
18. Martelli M.F., Aversa F., Bachar-Lustig E., et al. Transplants across human leukocyte antigen barriers. Seminars in Hematology 39 1 (2002) 48-56
19. Handgretinger R., Klingebiel T., Lang P., et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplantation 27 8 (2001) 777-783
20. Passweg J.R., Kuhne T., Gregor M., et al. Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants. Bone Marrow Transplantation 26 10 (2000) 1033-1036
21. Rowe J.M., and Lazarus H.M. Genetically haploidentical stem cell transplantation for acute leukemia. Bone Marrow Transplantation 27 7 (2001) 669-676
22. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 1 (1999) 333-339
23. Eyrich M., Lang P., Lal S., et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors. British Journal of Haematology 114 2 (2001) 422-432
24. Nguyen S., Dhedin N., Vernant J.P., et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 105 10 (2005) 4135-4142
25. Ruggeri L., Capanni M., Tosti A., et al. Innate immunity against hematological malignancies. Cytotherapy 4 4 (2002) 343-346
26. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 5562 (2002) 2097-2100
27. Ruggeri L., Capanni M., Martelli M.F., et al. Cellular therapy: exploiting NK cell alloreactivity in transplantation. Current Opinion in Hematology 8 6 (2001) 355-359
28. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 5426 (1999) 412-415
29. Davies S.M., Ruggieri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100 10 (2002) 3825-3827
30. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 3 (2003) 814-819
31. Gagne K., Brizard G., Gueglio B., et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Human Immunology 63 4 (2002) 271-280
32. Hsu K.C., Taylor C.A., O'Reilly R.J., et al. AML Patients lacking KIR ligand for donor KIR exhibit increased overall survival in HLA-identical sibling transplants. Biology of Blood and Marrow Transplantation 10 S1, 7 (2004)
33. Bishara A., De Santis D., Witt C.C., et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63 3 (2004) 204-211
34. Lowe E.J., Turner V., Handgretinger R., et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. British Journal of Haematology 123 2 (2003) 323-326
35. Cook M.A., Milligan D.W., Fegan C.D., et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 103 4 (2004) 1521-1526
36. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. Journal of Immunology 172 1 (2004) 644-650
37. Triplett B., Handgretinger R., Pui C.H., et al. KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood 107 3 (2006) 1238-1239
38. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 12 (1990) 2462-2465
39. Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95 1 (2000) 67-71
40. Guglielmi C., Arcese W., Dazzi F., et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100 2 (2002) 397-405
41. Soiffer R.J., Alyea E.P., Hochberg E., et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biology of Blood and Marrow Transplantation 8 11 (2002) 625-632
42. Lewalle P., Triffet A., Delforge A., et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplantation 31 1 (2003) 39-44
43. Naliboff B.D., Benton D., Solomon G.F., et al. Immunological changes in young and old adults during brief laboratory stress. Psychosomatic Medicine 53 2 (1991) 121-132
44. Schedlowski M., Falk A., Rohne A., et al. Catecholamines induce alterations of distribution and activity of human natural killer (NK) cells. Journal of Clinical Immunology 13 5 (1993) 344-351
45. Lassailly F., Sielleur I., Blaise D., et al. rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells. Bone Marrow Transplantation 35 1 (2005) 25-32
46. Tayebi H., Kuttler F., Saas P., et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Experimental Hematology 29 4 (2001) 458-470
47. Wolf C.E., Meyer M., and Riggert J. Leukapheresis for the extraction of monocytes and various lymphocyte subpopulations from peripheral blood: product quality and prediction of the yield using different harvest procedures. Vox Sanguinis 88 4 (2005) 249-255
48. Koehl U., Sorensen J., Esser R., et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells, Molecules and diseases 33 3 (2004) 261-266
49. Passweg J.R., Tichelli A., Meyer-Monard S., et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18 11 (2004) 1835-1838
50. Iyengar R., Handgretinger R., Babarin-Dorner A., et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 5 6 (2003) 479-484
51. Koehl U., Esser R., Zimmermann S., et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klinische Padiatrie 217 6 (2005) 345-350
52. Klingemann H.G., and Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 6 1 (2004) 15-22
53. Luhm J., Brand J.M., Koritke P., et al. Large-scale generation of natural killer lymphocytes for clinical application. Journal of hematotherapy and stem cell research 11 4 (2002) 651-657
54. Gentilini C., Hilbers U., Hartung G., et al. Early transfer of highly purified alloreactive CD56+CD3- NK-cells after haploidentical stem cell transplantation: promising results of a phase I study. Bone Marrow Transplantation 37 S1 (2006) S35
55. Slavin S., Morecki S., Shapira M., et al. Immunotherapy using rIL-2 activated mismatched donor lymphocytes positively selected for CD56+ for the treatment of resistant haematologic malignancies after stem cell transplantation. Bone Marrow Transplantation 33 S174 (2004)
56. Koehl U., Sörensen J., Esser R., et al. Immunotherapy with highly purified CD56+CD3- natural killer cells for paediatric patients after haploidentical stem cell transplantation. Bone Marrow Transplantation 37 S1 (2006) S35
57. Bethge W.A., Faul C., Bornhäuser M., et al. Haploidentical allogeneic haematopoietic cell transplantation in adults with CD3/CD19 depleted grafts and reduced-intensity conditioning: fast engraftment and low toxicity. Bone Marrow Transplantation 37 S1 (2006) S33
58. Bethge W.A., Haegele M., Faul C., et al. CD3/CD19 depleted as compared to CD34 selected grafts allow haploidentical allogeneic haematopoietic cell transplantation with faster engraftment and immune reconstitution. Bone Marrow Transplantation 37 S1 (2006) S33
59. Igarashi T., Wynberg J., Srinivasan R., et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104 1 (2004) 170-177
60. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 8 (2005) 3051-3057
61. Uharek L., Zeis M., Glass B., et al. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukemia 10 11 (1996) 1758-1764
62. Nagao F., Suzui M., Takeda K., et al. Mobilization of NK cells by exercise: downmodulation of adhesion molecules on NK cells by catecholamines. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 279 4 (2000) R1251-R1256
63. Nowbakht P., Ionescu M.C., Rohner A., et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 105 9 (2005) 3615-3622
64. Siegler U., Kalberer C.P., Nowbakht P., et al. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 19 12 (2005) 2215-2222
65. Langenkamp U., Rohner A., Siegler U., et al. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of AML cells to NK cell-mediated lysis. Bone Marrow Transplantation 37 S1 (2006) S23